北京博晖创新光电技术股份有限公司 2017 年第三季度报告全文 北京博晖创新光电技术股份有限公司 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证季度报告中财务报表的真实、准确、完整。 2 北京博晖创新光电技术股份有限公司 2017 年第三季度报告全文 2017 年第三季度报告 定 2017-06 2017 年 10 月 1 北京博晖创新光电技术股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,603,602,255.52 | 2,094,299,877.39 | | 24.32% | | 归属 ...

北京博晖创新光电技术股份有限公司 2017 年半年度报告全文 北京博晖创新光电技术股份有限公司 2017 年半年度报告 定 2017-04 2017 年 08 月 1 北京博晖创新光电技术股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、 计提商誉减值的风险 截止报告期，公司商誉总计为 112,678.43 万元,其中收购河北大安及广东卫 伦形成商誉合计 98,808.37 万元，收购 ADVION 形成商誉 13,870.07 万元。公司 会在每年年度终了时进行商誉减值测试，并根据减值测试结果决定是否计提商 誉减值准备。受未来经营所面临的多种不确定因素影响及本年度进入河北大安 原有股东沃森生物承诺的血浆采集量对赌期，如果本年度采浆量未达到承诺量 则存在发 ...

北京博晖创新光电技术股份有限公司 2017 年第一季度报告全文 北京博晖创新光电技术股份有限公司 2017 年第一季度报告 定 2017-03 2017 年 04 月 1 北京博晖创新光电技术股份有限公司 2017 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证季度报告中财务报表的真实、准确、完整。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 83,520,656.10 | 64,901,123.48 | 28.69% | | 归属于上市公司股东的净利润（元） | 1,394,918.33 | 2,306,136.96 | -39.51% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 1,115,578.70 | 1 ...

北京博晖创新光电技术股份有限公司 2016 年年度报告全文 北京博晖创新光电技术股份有限公司 2016 年年度报告 定 2017-01 2017 年 04 月 1 北京博晖创新光电技术股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司经本次董事会审议通过的利润分配预案为：以 821481858 为基数，向 全体股东每 10 股派发现金红利 0.03 元（含税），送红股 0 股（含税），以资本公 积金向全体股东每 10 股转增 0 股。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 5 | | --- | --- | | 第二节 | 公司简介和主要财务指标 9 | | 第三节 | 公司业务概要 19 | | 第四节 | 经营情况讨论与分析 ...

北京博晖创新光电技术股份有限公司 2016 年第三季度报告全文 北京博晖创新光电技术股份有限公司 2016 年第三季度报告 定 2016-06 2016 年 10 月 1 北京博晖创新光电技术股份有限公司 2016 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 √ 是 □ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度 | | --- | --- | --- | --- | --- | | | | | | 末增减 | | | | 调整前 | 调整后 | 调整后 | | 总资产（元） | 2,113,379,014.13 | 2,070,197,063.87 | 2,070,197,063.87 | 2.09% | | 归属于上市公司股东的净资产 （元） | 1,407,646,713.53 | 1,388,428,330.22 | 1,388,428,330.22 ...

北京博晖创新光电技术股份有限公司 2016 年半年度报告全文 北京博晖创新光电技术股份有限公司 2016 年半年度报告 定 2016-04 2016 年 08 月 1 北京博晖创新光电技术股份有限公司 2016 年半年度报告全文 第一节 重要提示、释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证年度报告中财务报告的真实、准确、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | 释义 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 本公司、公司、博晖创新 | 指 | 北京博晖创新光电技术股份有限公司 | | 博昂尼克 | 指 | 北京博昂尼克微流体技术有限公司 | | 河北大安、大安制药、大安公司 | 指 | 河北大安制药有限公司 | | 广东卫伦 | 指 | 广东卫伦生物制药有限公司 | | ...

Financial Performance - The company's operating revenue for 2015 was CNY 268,846,009.55, representing a 166.26% increase compared to CNY 100,969,495.36 in 2014[15]. - The net profit attributable to shareholders decreased by 68.85% to CNY 11,882,008.30 from CNY 38,138,794.33 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was CNY 16,256,772.99, down 45.01% from CNY 29,562,522.71 in 2014[15]. - The net cash flow from operating activities increased by 186.49% to CNY 88,950,522.99 from CNY 31,048,911.32 in 2014[15]. - The total assets at the end of 2015 reached CNY 2,070,197,063.87, a 158.99% increase from CNY 799,338,029.68 in 2014[15]. - The net assets attributable to shareholders increased by 91.74% to CNY 1,388,428,330.22 from CNY 724,126,579.89 in 2014[15]. - The basic earnings per share decreased by 70.72% to CNY 0.0303 from CNY 0.1035 in 2014[15]. - The weighted average return on equity was 1.07%, down from 5.36% in the previous year[15]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of CNY 0.03 per 10 shares, with no bonus shares issued[4]. - A cash dividend of CNY 1,227,317.81 (including tax) was distributed, representing 10.33% of the net profit attributable to shareholders for 2015[126]. - The total distributable profit as of December 31, 2015, was CNY 247,189,657.41[126]. - The remaining undistributed profits will be carried forward for future distribution[124]. - The total cash dividend for 2015 was fully paid out within the stipulated time frame after the approval of the shareholders' meeting[121]. Acquisitions and Business Expansion - The company completed the acquisition of 100% equity of Advion, expanding into mass spectrometry products and blood products[24]. - The company also acquired 48% of Hebei Daan Pharmaceutical Co., Ltd. and 30% of Guangdong Weilen Biopharmaceutical Co., Ltd., entering the blood products industry[24]. - The company completed the acquisition of 48% of Hebei Daan Pharmaceutical for CNY 646.12 million and 30% of Guangdong Weilen Biological Pharmaceutical for CNY 150 million, expanding its business into the blood products industry[34][43]. - The company is focused on expanding its market presence and developing new technologies in the field of optoelectronics[15]. - The company is actively working on expanding its plasma collection stations to increase plasma supply, which is currently limited[50]. - The company plans to diversify into the blood products industry, aligning with its long-term strategic goals[105]. Research and Development - Research and development expenditure amounted to ¥38,790,315.21, representing 14.43% of total revenue, despite a decrease of 7.82% in the proportion compared to the previous year[79][80]. - The company has developed several patented technologies, including a microfluidic time-resolved fluorescence immunoassay device, enhancing its competitive edge in the market[38]. - The company plans to increase R&D investment and recruit domestic and international technical talent to enhance its technological capabilities[109]. - The company is developing multiple product lines, including microfluidic products, which are crucial for its diagnostic business in 2016[111]. Market Trends and Industry Insights - The IVD market in China is expected to grow at an annual rate of 15-20%, driven by advancements in diagnostic technology and the expansion of application fields[26]. - The blood products industry in China is experiencing a supply-demand gap, with actual plasma demand exceeding 12,000 tons, while domestic collection can only meet half of this demand[28]. - The blood products industry in China is experiencing high demand, with significant growth potential as the market is still in the early stages of consolidation compared to international counterparts[32]. Financial Position and Assets - The company's total assets and net assets attributable to shareholders increased by 158.99% and 91.74%, reaching CNY 2,070.20 million and CNY 1,388.43 million respectively by the end of 2015[41]. - The company's goodwill increased by CNY 887.45 million due to the acquisitions of Hebei Daan and Advion[34]. - The company's fixed assets increased by 65.44% to CNY 134.83 million, primarily due to the consolidation of newly acquired entities[34]. Compliance and Governance - The company has maintained a clear and transparent profit distribution policy, ensuring the protection of minority shareholders' rights[122]. - The company has complied with all relevant regulations regarding profit distribution and capital increase proposals[122]. - The company has successfully completed all required disclosures and commitments related to its financial performance and acquisitions[131]. Shareholder Information - The largest shareholder, Du Jiangtao, holds 39.12% of the shares, totaling 160,040,230 shares, with an increase of 119,036,710 shares during the reporting period[170]. - The company has a total of 17,855 common shareholders at the end of the reporting period[170]. - The company has a total of 204,922,705 restricted shares at the end of the reporting period, with 99,358,720 shares released during the current period[165]. Employee and Management Structure - The company has a total of 499 employees, with 269 in the parent company and 230 in major subsidiaries[188]. - The total pre-tax remuneration for directors, supervisors, and senior management is 285.81 million yuan[187]. - The board of directors consists of nine members, including three independent directors[181].

北京博晖创新光电技术股份有限公司 2016 年第一季度报告全文 北京博晖创新光电技术股份有限公司 2016 年第一季度报告 定 2016-03 2016 年 04 月 1 北京博晖创新光电技术股份有限公司 2016 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杜江涛、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证季度报告中财务报告的真实、完整。 2 北京博晖创新光电技术股份有限公司 2016 年第一季度报告全文 第二节 公司基本情况 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 64,901,123.48 | 23,475,685.85 | 176.46% | | 归属于上市公司股东的净利润（元） | 2,306,136.96 | 4,496,176.76 ...

Financial Performance - Total revenue for the reporting period was CNY 77,049,653.99, representing a growth of 149.88% year-on-year[7]. - Net profit attributable to shareholders was CNY 6,469,145.30, a decrease of 50.85% compared to the same period last year[7]. - The company reported a net cash flow from operating activities of CNY 24,702,702.44, an increase of 284.61% year-to-date[7]. - The company's operating revenue for the year-to-date period reached 134.65 million yuan, representing a year-on-year increase of 79.93% due to an expanded consolidation scope and increased sales of element detection products and analytical instruments[24]. - The company reported a significant increase in cash and cash equivalents, with a year-end balance of 70.87 million RMB, a decrease of 83.5% compared to the beginning of the year due to cash acquisitions of Advion and Guangdong Weilin[25]. - The company reported a comprehensive income total of ¥10,436,854.47 for Q3 2015, compared to ¥12,878,004.69 in the same quarter of the previous year[100]. - The net profit for the current period was ¥28,392,891.69, down from ¥30,312,389.45, a decrease of about 6%[106]. Assets and Liabilities - Total assets reached CNY 2,050,202,073.35, an increase of 156.49% compared to the previous year[7]. - The total assets increased significantly, with fixed assets at 334.71 million RMB, a growth of 62.44% compared to the beginning of the year due to the consolidation of new companies[30]. - The company's total liabilities increased significantly, with other payables at 553.97 million RMB, a staggering increase of 42018.6% due to the incorporation of Hebei Daan's borrowings[38]. - The total liabilities of the company as of September 30, 2015, were 759,885,293.75 yuan, up from 72,768,192.45 yuan at the beginning of the year[92]. - The company's equity attributable to shareholders reached 1,404,690,613.67 yuan, compared to 724,126,579.89 yuan at the beginning of the year[93]. Investments and Acquisitions - The company has invested approximately CNY 195.35 million in the construction of a comprehensive R&D base, leading to increased depreciation and operational costs[10]. - The acquisition of Hebei Daan Pharmaceutical Co., Ltd. has expanded the company's business into blood products, posing management challenges[14]. - The company completed acquisitions of Hebei Daan and Advion, adding blood products and mass spectrometry products to its portfolio[58]. - The company has utilized CNY 25 million of the raised funds for the acquisition of Guangdong Weilan's 30% equity, with CNY 30.26 million remaining in the special account for raised funds[81]. - The company completed the acquisition of Advion for a total payment of $29,042,928, resulting in goodwill of $22,493,943[83]. Operational Costs and Expenses - The operating cost for the same period was 55.56 million yuan, up 252.29% year-on-year, primarily due to increased operating revenue and lower gross margins from acquired entities[24]. - Management expenses reached 44.38 million yuan, a 96.02% increase year-on-year, driven by the expanded consolidation scope and increased depreciation and operational costs from relocating to a new site[44]. - Sales expenses for the year-to-date period amounted to 22.02 million yuan, reflecting a year-on-year increase of 56.46% attributed to the expanded consolidation scope[44]. Risks and Challenges - The company faces risks related to the approval of new products, which could impact future revenue if not obtained in a timely manner[16]. - The company faces risks in new product development, which typically requires 3-5 years from initial investment to successful product registration[64]. - The supply of raw materials for blood products is currently tight due to regulatory constraints, directly impacting production capacity[69]. - Daan Pharmaceutical has a high debt-to-asset ratio, increasing its financial risk due to significant funding needs for R&D[71]. Research and Development - The company plans to accelerate new product development across multiple product lines to enhance competitiveness[11]. - The company has implemented a strategy to enhance its talent acquisition, particularly in technical roles, to support its research and development efforts[61]. - The company has established three major technology platforms: atomic absorption-based human element detection, immunofluorescence chromatography-based rapid immunodiagnosis, and microfluidic control-based molecular diagnosis[64]. Cash Flow - Cash received from sales and services was 133.23 million yuan, up 74.15% year-on-year, primarily due to the expanded consolidation scope[47]. - The net cash flow from operating activities for Q3 2015 was ¥24,702,702.44, a significant increase from ¥6,422,781.10 in Q3 2014, representing a growth of approximately 285%[113]. - The total cash inflow from operating activities for the year-to-date was ¥119,133,031.62, up from ¥84,450,775.33 in the previous year, marking a growth of about 41%[115].

Financial Performance - Total operating revenue for the first half of 2015 was ¥57,602,917.39, representing a 30.91% increase compared to ¥44,002,936.33 in the same period last year[15]. - Net profit attributable to ordinary shareholders was ¥23,012,548.77, up 24.54% from ¥18,477,728.66 year-on-year[15]. - Net cash flow from operating activities increased by 135.80% to ¥19,200,570.34, compared to ¥8,142,654.20 in the previous year[15]. - Basic earnings per share rose to ¥0.1349, reflecting a 19.59% increase from ¥0.1128 in the same period last year[15]. - The company reported a decrease of 36.83% in net profit after deducting non-recurring gains and losses, totaling ¥10,631,213.11 compared to ¥16,829,697.02 last year[15]. - The company achieved operating revenue of 57,602,917.39 CNY, a year-on-year increase of 30.91%[30]. - The net profit attributable to shareholders increased significantly to 2,301.25 CNY, a growth of 24.54%[30]. - The company reported a net cash increase of cash and cash equivalents of -219.03 million yuan, a decrease of 24.45% year-on-year[33]. - The company reported a comprehensive income total of 19,471,889.26 CNY for the period[152]. Assets and Liabilities - Total assets reached ¥2,019,939,760.57, a significant increase of 152.70% from ¥799,338,029.68 at the end of the previous year[15]. - The total assets as of the end of the reporting period were CNY 1,482,202,782.48, up from CNY 806,262,923.73 at the beginning of the year, indicating a growth of 83.7%[136]. - The total liabilities were CNY 65,747,829.58, a decrease of 7.3% from CNY 70,801,229.86 in the previous period[137]. - The owner's equity totaled CNY 1,416,454,952.90, which is an increase of 92.9% compared to CNY 735,461,693.87 at the beginning of the year[137]. Operational Costs and Expenses - Operating costs rose by 72.80% to 16,210,164.14 CNY, primarily due to increased sales of trace element products and lower gross margins from Hebei Daan[32]. - The operating profit decreased by 62.67% to 684.52 CNY due to the inclusion of Hebei Daan's financial data and increased period expenses[30]. - Research and development expenses increased by 46.48% to 11,441,186.81 CNY, reflecting higher personnel costs and R&D material expenses[32]. - Management expenses surged by 92.67% to 23,504,125.22 CNY, driven by increased R&D investments and costs associated with the acquisition of Hebei Daan[32]. Acquisitions and Investments - The company plans to issue 40,712,969 shares to acquire a 48% stake in Hebei Daan Pharmaceutical Co., Ltd., with the transaction date set for May 31, 2015[15]. - The company completed the acquisition of 48% equity in Hebei Daan Pharmaceutical Co., Ltd. for a transaction price of 662.4 million CNY, which is expected to enhance the company's competitiveness and sustainable development[87]. - The company has paid 17,419.6 million CNY for the acquisition of 100% equity in Advion, Inc., with the asset transfer procedures still pending[87]. - The company plans to allocate 60 million CNY of remaining raised funds for the acquisition of a 30% stake in Guangdong Weirun, with 15 million CNY already invested[64]. Research and Development - The company is expanding its product lines and enhancing R&D capabilities to maintain competitiveness in the medical device sector[22]. - The company has made progress in R&D, focusing on microfluidic technology, with advancements in production processes and chip development[42]. - The company has established three major technology platforms for product development, which are based on atomic absorption, immunofluorescence, and microfluidic control technologies[52]. Risks and Challenges - The company faces risks related to increased operational costs and depreciation from the new comprehensive R&D base, which could impact short-term performance[21]. - The acquisition of Daan Pharmaceutical introduces management challenges that could affect ongoing operations if not addressed promptly[24]. - The company is at risk of delays in product registration, particularly for intravenous immunoglobulin, which could adversely affect future performance[27]. - The company faces risks related to the approval of blood plasma component transfers, which are crucial for the production of intravenous immunoglobulin[55]. - The company has a high debt ratio, which poses a repayment risk due to the capital-intensive nature of the blood products industry[59]. Shareholder Information - The total number of shares outstanding is 163,840,000, with no changes in the overall structure[113]. - Major shareholders include Du Jiangtao with 25.03% (41,003,520 shares) and Yang Qi with 15.75% (25,806,400 shares)[119]. - Du Jiangtao's shares are partially pledged, with 32,760,000 shares under pledge[119]. - The number of shareholders at the end of the reporting period was 5,088[118]. Financial Reporting and Compliance - The financial report for the first half of 2015 was not audited, which may affect the reliability of the financial data presented[128]. - The company has not reported any major changes in the feasibility of its projects[71]. - The company has not disclosed any significant contracts or agreements that are applicable during the reporting period[103]. - The financial statements are prepared based on the going concern assumption, indicating no significant uncertainty regarding the company's ability to continue operations for the next 12 months[177].